Omlonti (omidenepag isopropyl) / Santen, Ube Corp 
Welcome,         Profile    Billing    Logout  
 6 Diseases   1 Trial   1 Trial   125 News 


12»
  • ||||||||||  Omlonti (omidenepag isopropyl) / Santen, Ube Corp
    Preclinical, Journal:  Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys. (Pubmed Central) -  Nov 15, 2024   
    Neither OMD nor OMDI interacted with the target receptors or enzymes of other antiglaucoma agents, suggesting that OMD interacts highly selectively with EP2 receptors. OMDI is a specific antiglaucoma agent that interacts selectively with ocular EP2 receptors.
  • ||||||||||  Omlonti (omidenepag isopropyl) / Santen, Ube Corp, Dupixent (dupilumab) / Sanofi, Regeneron
    Journal:  Activation of the PGE2-EP2 pathway as a potential drug target for treating eosinophilic rhinosinusitis. (Pubmed Central) -  Jul 17, 2024   
    Current treatments of eosinophilic chronic rhinosinusitis (ECRS) involve corticosteroids with various adverse effects and costly therapies such as dupilumab, highlighting the need for improved treatments...ECRS is often associated with aspirin-induced asthma, suggesting that dysregulation of lipid mediators in the nasal mucosa may underlie ECRS pathology...These results suggest that the present model using Ptges-deficient mice is more relevant to human ECRS than are previously reported models and that eosinophilic inflammation in the nasal mucosa can be efficiently blocked by activation of the PGE2-EP2 pathway. Furthermore, our findings suggest that drug repositioning of omidenepag isopropyl may be useful for treatment of patients with ECRS.
  • ||||||||||  Omlonti (omidenepag isopropyl) / Santen, Ube Corp
    Trial completion:  DE-117 Spectrum 5 Study (clinicaltrials.gov) -  Aug 30, 2023   
    P3,  N=107, Completed, 
    Faricimab-svoa (Vabysmo) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti) for Glaucoma and Ocular Hypertension. Unknown status --> Completed
  • ||||||||||  Review, Journal:  Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients. (Pubmed Central) -  Jun 28, 2023   
    A unique nitric oxide-donating conjugate of latanoprost, an FP-receptor prostaglandin (PG; latanoprostene bunod), new rho kinase inhibitors (ripasudil; netarsudil), a novel non-PG EP2-receptor-selective agonist (omidenepag isopropyl), and a form of FP-receptor PG in a slow-release intracameral implant (Durysta) represent the additions to the pharmaceutical toolchest to mitigate the ravages of OHT. Despite these advances, early diagnosis of OHT and glaucoma still lags behind and would benefit from further concerted effort and attention.
  • ||||||||||  SNJ-1656 / Senju, Novartis, Omlonti (omidenepag isopropyl) / Santen, Ube Industries, AMA0076 / Peak Bio
    Review, Journal:  Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment. (Pubmed Central) -  Jun 19, 2023   
    However, translation of the novel animal-based findings to the human conditions remains to be demonstrated but represent viable targets, especially EP-receptor agonists (e.g. omidenepag isopropyl; AL-6598; butaprost), mixed activity serotonin/dopamine receptor agonists (e.g. cabergoline), rho kinase inhibitors (e.g. AMA0076, Y39983), CACNA2D1-gene product inhibitors (e.g. pregabalin), melatonin receptor agonists, and certain K-channel openers (e.g. nicorandil, pinacidil). Other drug candidates and targets were also identified and will be discussed.
  • ||||||||||  Review, Journal:  FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma. (Pubmed Central) -  Mar 28, 2023   
    Moreover, a selective non-PG prostanoid EP2 receptor agonist, omidenepag isopropyl (OMDI), was discovered, characterized, and has been approved in the United States, Japan and several other Asian countries for treating OHT/glaucoma...This has successfully been achieved by the recent approval and introduction of miniature devices into the anterior chamber by minimally invasive glaucoma surgeries. This review covers the three major aspects mentioned above to highlight the etiology of OHT/glaucoma, and the pharmacotherapeutics and devices that can be used to combat this blinding ocular disease.
  • ||||||||||  Omlonti (omidenepag isopropyl) / Santen, Ube Industries
    Journal:  Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells. (Pubmed Central) -  Jan 12, 2023   
    Omidenepag isopropyl (OMDI) is an intraocular pressure (IOP)-lowering drug used to treat glaucoma...Reduction in the extracellular matrix contributes to the decrease in outflow resistance, suggesting that the downregulation of the two related genes may be one of the factors influencing the IOP-lowering effect of OMDI. Our findings provide insights for the use of OMDI in clinical practice.
  • ||||||||||  Omlonti (omidenepag isopropyl) / Santen, Ube Industries
    Journal:  Omidenepag Isopropyl. (Pubmed Central) -  Dec 23, 2022   
    Our findings provide insights for the use of OMDI in clinical practice. No abstract available
  • ||||||||||  P2 data, Review, Journal:  Emerging drugs for the treatment of glaucoma: A review of phase II & III trials. (Pubmed Central) -  Nov 9, 2022   
    However, the availability of generic prostaglandin analogs may limit adoption of these novel compounds as first line agents, except for certain subgroups of glaucoma patients. Use as adjuvant or second line therapy appears more likely for the majority of glaucoma patients.
  • ||||||||||  Eybelis (omidenepag isopropyl) / Santen, Ube Industries
    Journal:  Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan. (Pubmed Central) -  Jun 25, 2022   
    Dose-based anti-glaucoma medication prescription was analyzed using the government-provided most recent database on a national scale. The results provide the up-to-date real-world glaucoma medication prescriptions where the country has the highest aging rate in the world.
  • ||||||||||  Eybelis (omidenepag isopropyl) / Santen, Ube Industries
    Clinical, Journal:  Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need. (Pubmed Central) -  Jun 15, 2022   
    OMDI appears to provide IOP reductions comparable to PGAs, but without PAPS-related undesirable effects. OMDI may offer a suitable long-term option for patients who demonstrate decreased efficacy, or failure, of PGAs, plus patients with significant PAPS, while fulfilling international guidelines.
  • ||||||||||  Eybelis (omidenepag isopropyl) / Santen, Ube Industries
    Clinical, Journal:  Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report. (Pubmed Central) -  Jan 18, 2022   
    Decreased vision and cystoid macular edema (CME) developed in phakic eyes of a patient who underwent laser iridotomy after changing the glaucoma eye drops from carteolol 2% long-acting ophthalmic solution to omidenepag isopropyl 0.002%. CME completely disappeared at approximately 2 months after discontinuation of omidenepag isopropyl in conjunction with the use of bromfenac sodium 0.1%.
  • ||||||||||  Zioptan (tafluprost) / Santen, Merck (MSD), Rhopressa (netarsudil) / Aerie Pharma
    Review, Journal:  Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies. (Pubmed Central) -  Oct 5, 2021   
    TM/SC outflow enhancing drugs are also effective ocular hypotensive agents (e.g., rho kinase inhibitors like ripasudil and netarsudil; and latanoprostene bunod, a conjugate of a nitric oxide donor and latanoprost)...Other IOP-lowering drugs and devices on the horizon will be also discussed. Additionally, since elevated IOP is only one of many risk factors for development of glaucomatous optic neuropathy, a treatise of the role of inflammatory neurodegeneration of the optic nerve and retinal ganglion cells and appropriate neuroprotective strategies to mitigate this disease will also be reviewed and discussed.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
    Observational data, Retrospective data, Journal:  Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy. (Pubmed Central) -  Sep 10, 2021   
    The PAP graded using SU-PAP reflects the degree of overestimation of the IOPGAT and different severities of PAP among the different prostaglandins. SU-PAP, the grade system constructed based on the underlining mechanisms of PAP, is a simple grading system for PAP that is feasible for use in a real-world clinical situation.
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Preclinical, Journal:  The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice. (Pubmed Central) -  Aug 4, 2021   
    Purpose: The present study investigated the effects of the antiglaucoma agent and selective E2 receptor agonist omidenepag isopropyl (OMDI) on eyelash growth in comparison with a prostaglandin analog (prostamide receptor agonist) in mice. Unlike existing prostaglandin analogs, our findings indicate that OMDI has no effect on eyelash growth in mice, suggesting that it may be a promising antiglaucoma agent with a reduced number of adverse effects.
  • ||||||||||  Eybelis (omidenepag isopropyl) / Santen, Ube Industries
    EW-11 Omidenepag Isopropyl: Global Clinical Trial Experience in Glaucoma (MBCR - ASCRS Tap Room, Bayside Hall C) -  Jul 19, 2021 - Abstract #ASCRSASOA2021ASCRS_ASOA_602;    
    Unlike existing prostaglandin analogs, our findings indicate that OMDI has no effect on eyelash growth in mice, suggesting that it may be a promising antiglaucoma agent with a reduced number of adverse effects. Description Join the Silent Theater
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
    Journal:  Cystoid macula edema related to cataract surgery and topical prostaglandin analogs: mechanism, diagnosis, and management. (Pubmed Central) -  Jul 8, 2021   
    It has been proposed that eyes with elevated intraocular pressure after cataract surgery, including those treated with prostaglandin analog eye drops, may be at higher risk for developing CME. We summarize the current knowledge of the molecular mechanisms underlying CME, the potential role of ocular surgery and topical glaucoma medication in increasing the risk of CME, the newly developed imaging methods for diagnosing CME, and the clinical management of CME.